Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SAGITTARIUS: Precision Medicine in Stage II/III Colon Cancer
NCT06490536Phase 3Recruiting
- Sponsor
- IFOM
- Start
- Oct 2024
- Primary completion
- Mar 2026
- Modality
- Antibody Conjugates, Nanoparticles, Monoclonal Antibodies
- Countries
- 3
01
Overview
Phase 3, randomised, open-label trial of nivolumab, ipilimumab, trastuzumab, pertuzumab, panitumumab and 2 more in colon cancer, sponsored by IFOM. Started Oct 2024; status: recruiting.
02
Drugs
03
Conditions
colon cancer
Beyond the preview
Go deeper on NCT06490536.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06490536.